Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.10B | 940.20M | 747.72M | 801.22M | 702.80M | 498.83M | Gross Profit |
513.31M | 489.57M | 367.69M | 412.99M | 376.21M | 260.52M | EBIT |
-178.33M | -99.13M | -233.23M | -61.81M | 8.81M | -7.96M | EBITDA |
-150.68M | -99.13M | -194.66M | -72.31M | 36.50M | -13.03M | Net Income Common Stockholders |
-183.87M | -96.03M | -222.61M | -94.59M | 15.57M | -34.38M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
467.81M | 438.33M | 467.91M | 616.90M | 623.81M | 484.94M | Total Assets |
941.04M | 967.66M | 952.66M | 1.05B | 905.14M | 716.41M | Total Debt |
477.55M | 473.56M | 415.67M | 419.88M | 314.67M | 228.32M | Net Debt |
418.57M | 404.33M | 356.80M | 247.36M | 243.49M | 133.71M | Total Liabilities |
697.98M | 704.56M | 639.03M | 612.84M | 472.02M | 350.11M | Stockholders Equity |
243.06M | 263.10M | 313.63M | 439.95M | 433.11M | 366.31M |
Cash Flow | Free Cash Flow | ||||
-50.20M | 4.99M | -83.41M | 7.51M | 87.85M | -7.63M | Operating Cash Flow |
13.94M | 24.23M | -31.81M | 50.46M | 111.36M | 24.67M | Investing Cash Flow |
-9.24M | -23.48M | -85.74M | 33.17M | -186.88M | -296.06M | Financing Cash Flow |
-9.91M | 8.37M | 4.11M | 16.88M | 51.93M | 314.44M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $34.25B | 63.73 | 23.72% | ― | 9.11% | -17.87% | |
80 Outperform | $1.84B | 28.07 | 19.36% | ― | 34.43% | 31.90% | |
76 Outperform | $23.05B | 58.40 | 37.92% | ― | 23.49% | 71.25% | |
65 Neutral | $1.25B | 15.97 | 5.12% | ― | -0.05% | ― | |
63 Neutral | $2.45B | 30.62 | -19.69% | ― | 7.97% | -592.40% | |
55 Neutral | $1.57B | ― | -92.31% | ― | 27.65% | -28.22% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% |
On May 16, 2025, Tandem Diabetes Care received CE mark approval for its Tandem Mobi insulin delivery system with Control-IQ+ technology. The company plans to pursue further regulatory and pre-commercial activities in the EU, aiming for commercial launches by the end of 2025.
The most recent analyst rating on (TNDM) stock is a Hold with a $46.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.